Compare Acutaas Chemical with Similar Stocks
Dashboard
Company has a Debt to Equity ratio (avg) of 0.05 times
Healthy long term growth as Net Sales has grown by an annual rate of 30.30% and Operating profit at 43.36%
The company has declared Positive results for the last 8 consecutive quarters
With ROE of 21.5, it has a Very Expensive valuation with a 16 Price to Book Value
High Institutional Holdings at 41.17%
Stock DNA
Pharmaceuticals & Biotechnology
INR 25,794 Cr (Small Cap)
69.00
44
0.05%
-0.11
21.54%
16.01
Total Returns (Price + Dividend) 
Latest dividend: 1.5000000000000002 per share ex-dividend date: Sep-18-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Acutaas Chemicals Ltd Downgraded to Hold Amid Mixed Financial and Technical Signals
Acutaas Chemicals Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 30 July 2026. This adjustment reflects a nuanced assessment across four key parameters: Quality, Valuation, Financial Trend, and Technicals. Despite strong long-term growth and robust institutional backing, recent quarterly performance and technical indicators have tempered enthusiasm, prompting a more cautious stance among investors.
Read full news article
Acutaas Chemicals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
Acutaas Chemicals Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, reflected in a downgrade of its Mojo Grade from Buy to Hold as of 30 July 2026. Despite a strong year-to-date return of 89.9%, recent price action and technical indicators suggest a cautious stance for investors amid mixed signals from key momentum and trend metrics.
Read full news article
Acutaas Chemicals Ltd is Rated Buy by MarketsMOJO
Acutaas Chemicals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 24 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 July 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read full news article Announcements 
Corporate Actions 
No Upcoming Board Meetings
Acutaas Chemicals Ltd has declared 30% dividend, ex-date: 18 Sep 25
Acutaas Chemicals Ltd has announced 5:10 stock split, ex-date: 25 Apr 25
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 32 Schemes (14.17%)
Held by 244 FIIs (21.61%)
Nareshkumar Ramjibhai Patel (17.69%)
Kotak Mahindra Trustee Co Ltd A/c Kotak Multicap Fund (3.95%)
21.72%
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is -23.82% vs 10.06% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is -43.64% vs 22.05% in Mar 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 21.26% vs 29.85% in Sep 2024
Growth in half year ended Sep 2025 is 127.24% vs 5,794.25% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 29.81% vs 41.80% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 133.28% vs 446.14% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 33.02% vs 40.34% in Mar 2025
YoY Growth in year ended Mar 2026 is 124.47% vs 271.08% in Mar 2025






